CanSino Biologics, Inc. Class H (6185) Stock Statistics & Valuation Metrics

CanSino Biologics, Inc. Class H has a market cap or net worth of HK$9.49B. The enterprise value is HK$6.53B.

CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

CanSino Biologics, Inc. Class H’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -24.72%.

The current PE Ratio of CanSino Biologics, Inc. Class H is -3.41. CanSino Biologics, Inc. Class H’s PEG ratio is -0.06.

In the last 12 months, CanSino Biologics, Inc. Class H had revenue of 345.18M and earned -1.48B in profits. Earnings per share was -6.01.

In the last 12 months, operating cash flow was -368.56M and capital expenditures 0.00, giving a free cash flow of ― billion.

CanSino Biologics, Inc. Class H pays an annual dividend of HK$0.937, resulting in a dividend yield of ―

CanSino Biologics, Inc. Class H upcoming earnings date is Apr 29, 2025, TBA Not Confirmed.

CanSino Biologics, Inc. Class H as a current ratio of 2.00, with Debt / Equity ratio of 43.43%

In the past 12 months, CanSino Biologics, Inc. Class H has paid -11.45M in taxes.

CanSino Biologics, Inc. Class H EV to EBITDA ratio is -3.47, with an EV/FCF ratio of -3.74.

CanSino Biologics, Inc. Class H has HK$3.53B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -HK$1.33B billion.

Gross margin is 14.38%, with operating margin of -589.60%, and net profit margin of -429.55%.

The average price target for CanSino Biologics, Inc. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―